Chemotherapy-induced Activation of ADAM-17: a Novel Mechanism of Drug Resistance in Colorectal Cancer

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2010 Jun 24

PMID 20570921

Citations 58

Authors

Joan N Kyula

Sandra Van Schaeybroeck

Joanne Doherty

Catherine S Fenning

Daniel B Longley

Patrick G Johnston

Affiliations

Soon will be listed here.

Abstract

Purpose: We have shown previously that exposure to anticancer drugs can trigger the activation of human epidermal receptor survival pathways in colorectal cancer (CRC). In this study, we examined the role of ADAMs (a disintegrin and metalloproteinases) and soluble growth factors in this acute drug resistance mechanism.

Experimental Design: In vitro and in vivo models of CRC were assessed. ADAM-17 activity was measured using a fluorometric assay. Ligand shedding was assessed by ELISA or Western blotting. Apoptosis was assessed by flow cytometry and Western blotting.

Results: Chemotherapy (5-fluorouracil) treatment resulted in acute increases in transforming growth factor-alpha, amphiregulin, and heregulin ligand shedding in vitro and in vivo that correlated with significantly increased ADAM-17 activity. Small interfering RNA-mediated silencing and pharmacologic inhibition confirmed that ADAM-17 was the principal ADAM involved in this prosurvival response. Furthermore, overexpression of ADAM-17 significantly decreased the effect of chemotherapy on tumor growth and apoptosis. Mechanistically, we found that ADAM-17 not only regulated phosphorylation of human epidermal receptors but also increased the activity of a number of other growth factor receptors, such as insulin-like growth factor-I receptor and vascular endothelial growth factor receptor.

Conclusions: Chemotherapy acutely activates ADAM-17, which results in growth factor shedding, growth factor receptor activation, and drug resistance in CRC tumors. Thus, pharmacologic inhibition of ADAM-17 in conjunction with chemotherapy may have therapeutic potential for the treatment of CRC.

Citing Articles

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids.

Rogmans C, Dittrich J, Hamm E, Weimer J, Holthaus D, Arnold N Sci Rep. 2024; 14(1):26926.

PMID: 39506058 PMC: 11541916. DOI: 10.1038/s41598-024-78442-y.

Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα-TRAF3-TAK1-MAPK axis.

Xie L, Xue F, Cheng C, Sui W, Zhang J, Meng L Signal Transduct Target Ther. 2024; 9(1):273.

PMID: 39406701 PMC: 11480360. DOI: 10.1038/s41392-024-01977-z.

Inhibition of ADAM17 increases the cytotoxic effect of cisplatin in cervical spheroids and organoids.

Holthaus D, Rogmans C, Gursinski I, Quevedo-Olmos A, Ehsani M, Mangler M Front Oncol. 2024; 14:1432239.

PMID: 39286024 PMC: 11402614. DOI: 10.3389/fonc.2024.1432239.

Application of Nanoparticles in the Diagnosis and Treatment of Colorectal Cancer.

Song Q, Zheng Y, Zhong G, Wang S, He C, Li M Anticancer Agents Med Chem. 2024; 24(18):1305-1326.

PMID: 39129164 PMC: 11497148. DOI: 10.2174/0118715206323900240807110122.

Competitive endogenous RNA networks: Decoding the role of long non-coding RNAs and circular RNAs in colorectal cancer chemoresistance.

Khalafizadeh A, Hashemizadegan S, Shokri F, Bakhshinejad B, Jabbari K, Motavaf M J Cell Mol Med. 2024; 28(7):e18197.

PMID: 38506091 PMC: 10951891. DOI: 10.1111/jcmm.18197.

References

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

Zhou B, Peyton M, He B, Liu C, Girard L, Caudler E . Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell. 2006; 10(1):39-50. PMC: 4451119. DOI: 10.1016/j.ccr.2006.05.024. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Darmoul D, Gratio V, Devaud H, Laburthe M . Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004; 279(20):20927-34. DOI: 10.1074/jbc.M401430200. View

Montero J, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A . Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci. 2000; 16(5):631-48. DOI: 10.1006/mcne.2000.0896. View

Burgess A, Cho H, Eigenbrot C, Ferguson K, Garrett T, Leahy D . An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003; 12(3):541-52. DOI: 10.1016/s1097-2765(03)00350-2. View

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Salomon D, Brandt R, Ciardiello F, Normanno N . Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19(3):183-232. DOI: 10.1016/1040-8428(94)00144-i. View

Solimini N, Luo J, Elledge S . Non-oncogene addiction and the stress phenotype of cancer cells. Cell. 2007; 130(6):986-8. DOI: 10.1016/j.cell.2007.09.007. View

10.

Fridman J, Caulder E, Hansbury M, Liu X, Yang G, Wang Q . Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res. 2007; 13(6):1892-902. DOI: 10.1158/1078-0432.CCR-06-2116. View

11.

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

12.

Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim J, Langley R . Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis. 2008; 25(4):477-89. DOI: 10.1007/s10585-008-9153-7. View

13.

Seals D, Courtneidge S . The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003; 17(1):7-30. DOI: 10.1101/gad.1039703. View

14.

Hundhausen C, Misztela D, Berkhout T, Broadway N, Saftig P, Reiss K . The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003; 102(4):1186-95. DOI: 10.1182/blood-2002-12-3775. View

15.

Kaulfuss S, Burfeind P, Gaedcke J, Scharf J . Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther. 2009; 8(4):821-33. DOI: 10.1158/1535-7163.MCT-09-0058. View

16.

Diaz-Rodriguez E, Carlos Montero J, Esparis-Ogando A, Yuste L, Pandiella A . Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol Biol Cell. 2002; 13(6):2031-44. PMC: 117622. DOI: 10.1091/mbc.01-11-0561. View

17.

Van Schaeybroeck S, Kelly D, Kyula J, Stokesberry S, Fennell D, Johnston P . Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. Cancer Res. 2008; 68(20):8312-21. PMC: 2596349. DOI: 10.1158/0008-5472.CAN-07-6736. View

18.

Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, Ohara H . The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology. 2004; 127(2):559-69. DOI: 10.1053/j.gastro.2004.05.017. View

19.

Sunnarborg S, Hinkle C, Stevenson M, Russell W, Raska C, Peschon J . Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem. 2002; 277(15):12838-45. DOI: 10.1074/jbc.M112050200. View

20.

Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E . Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005; 11(20):7480-9. DOI: 10.1158/1078-0432.CCR-05-0328. View